Barrett's esophagus: Model of neoplastic progression

World Journal of Surgery

Volumn 27, Issue 9, 2003, Pages 1009-1013

  Ramel, Stig ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; PROTEIN P16; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME 17P; CHROMOSOME 5Q; COLON POLYPOSIS; DNA CONTENT; ESOPHAGUS CARCINOMA; ESOPHAGUS TUMOR; GENE MUTATION; GENETICS; HISTOLOGY; HUMAN; INTESTINE METAPLASIA; PATHOLOGY; PRECANCER; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS;

EID: 0141765740     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-003-7053-1     Document Type: Article

References (78)

1. Burgess JN, Payne WS, Andersen HA, et al. Barrett esophagus: the columnar-epithelial-lined lower esophagus. Mayo Clin. Proc. 1971;46:728
2. Spechler SJ. Barrett's esophagus. Semin. Gastrointest. Dis. 1996;7:51
3. Paull A, Trier JS, Dalton D, et al. The histologic spectrum of Barrett's esophagus. N. Engl. J. Med. 1976;295:476
4. Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus: comparison of benign and malignant cases. Ann. Surg. 1983;198:554
5. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum. Pathol. 1992;23:475
6. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol. Clin. North Am. 1991;20:791
7. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North Am. 1991;20:817
8. Sjogren RW, Johnson LF. Barrett's esophagus: a review. Am. J. Med. 1983;74:313
9. Spechler SJ, Goyal RK. Barrett's esophagus. N. Engl. J. Med. 1986;315:362
10. Ribet M, Mensier E, Pruvot FR. Barrett's esophagus and adenocarcinoma. Eur. J. Cardiothorac. Surg. 1987;1:29
11. Fennerty MB, Sampliner RE, Garewal HS. Review article: Barrett's oesophagus; cancer risk, biology and therapeutic management. Aliment. Pharmacol. Ther. 1993;7:339
12. Dent J, Bremner CG, Collen MJ, et al. Barrett's oesophagus. J. Gastroenterol. Hepatol. 1991;6:1
13. Reid BJ, Haggitt RC, Rubin CE, et al. Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1
14. Hameeteman W, Tytgat GNJ, Houthoff HJ, et al. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249
15. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212
16. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40
17. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94:81
18. Levine DS, Haggitt RC, Irvine S, et al. Natural history of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996;110:550A
19. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23
20. Barrett MT, Galipeau PC, Sanchez CA, et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996;12:1873
21. Jankowski J, Coghill G, Hopwood D, et al. Oncogenes and oncosuppressor gene in adenocarcinoma of the oesophagus. Gut 1992;33:1033
22. Haggitt RC, Reid BJ, Rabinovitch PS, et al. Barrett's esophagus: correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am. J. Pathol. 1988;131:53
23. Hamilton SR, Smith RRL. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am. J. Clin. Pathol. 1987;87:301
24. McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum. Pathol. 1992;23:479
25. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441
26. Mufti SI, Zirvi KA, Garewal HS. Precancerous lesions and biologic markers in esophageal cancer. Cancer Detect. Prev. 1991;15:291
27. Li H. Malignant Barrett's oesophagus. Eur. J. Cancer Prev. 1993;2:47
28. Krishnadath KK, van Blankenstein M, Tilanus HW. Prognostic value of p53 in Barrett's oesophagus. Eur. J. Gastroenterol. Hepatol. 1995;7:81
29. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988;19:166
30. McKinley MJ, Budman DR, Grueneberg D, et al. DNA content in Barrett's esophagus and esophageal malignancy. Am. J. Gastroenterol. 1987;82:1012
31. Reid BJ, Haggitt RC, Rubin CE, et al. Flow cytometry complements histology in detecting patients at risk for Barrett's adenocarcinoma. Gastroenterology 1986;90:1600
32. Khan M, Bui HX, del Rosario A, et al. Role of DNA content determination by image analysis in confirmation of dysplasia in Barrett's esophagus. Mod. Pathol. 1994;7:169
33. Rabinovitch PS, Reid BJ, Haggitt RC, et al. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab. Invest. 1988;60:65
34. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815
35. Raskind WH, Norwood T, Levine DS, et al. Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res. 1992;52:2946
36. Blount PL, Rabinovitch PS, Haggitt RC, et al. Early Barrett's adenocarcinoma arises within a single aneuploid population. Gastroenterology 1990;98:A273
37. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867
38. Blount PL, Galipeau PC, Sanchez CA, et al. 17p Allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res. 1994;54:2292
39. Blount PL, Meltzer SJ, Yin J, et al. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 1993;90:3221
40. Blount PL, Ramel S, Raskind WH, et al. 17p Allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res. 1991; 51:5482
41. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) Allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. U. S. A. 1996;93:7081
42. Meltzer SJ, Yin J, Manin B, et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res. 1994;54:3379
43. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119
44. Gray MR, Hall PA, Nash J, et al. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769
45. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26
46. Jankowski J, McMenemin R, Hopwood D, et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin. Sci. Colch. 1991;81:663
47. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984;133:1710
48. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629
49. Shackney SE, Smith CA, Miller BW, et al. Model for the genetic evolution of human solid tumors. Cancer Res. 1989;49:3344
50. Weinert TA, Hartwell LH. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 1988;241:317
51. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043
52. Gonzalez MV, Artimez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J. Clin. Pathol. 1997;50:212
53. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012
54. Krishnadath KK, Tilanus HW, Alers JC, et al. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Cytometry 1994;15:176
55. Meltzer SJ. The molecular biology of esophageal carcinoma. Recent Results Cancer Res. 1996;142:1
56. Neshat K, Sanchez CA, Galipeau PC, et al. p53 Mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589
57. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. U. S. A. 1990;87:9958
58. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675
59. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705
60. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988;319:525
61. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993;53:846
62. Campomenosi P, Conio M, Bogliolo M, et al. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol. Biomarkers Prev. 1996;5:559
63. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980
64. Reid BJ, Barrett MT, Galipeau PC, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur. J. Cancer Prev. 1996;5:57
65. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science 1995;267:1353
66. Flejou JF, Potet F, Muzeau F, et al. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J. Clin. Pathol. 1993;46:330
67. Flejou JF, Paraf F, Potet F, et al. p53 Protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance. Histopathology 1994;24:487
68. Flejou JF, Potet F, Muzeau F, et al. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J. Clin. Pathol. 1993;46:330
69. Krishnadath KK, Mulder AH, Tilanus HW. p53 Protein overexpression in Barrett's adenocarcinoma and Barrett's esophagus in paraffin embedded tissue. Gastroenterology 1993;104:A1045
70. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J. Pathol. 1995;175:175
71. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220
72. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993;329:1318
73. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436
74. Spruck CH, Gonzalez-Zulueta M, Shibata A, et al. p16 Gene in uncultured tumours. Nature 1994;370:183
75. Zhang SY, Klein-Szanto AJ, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res. 1994;54:5050
76. Zhou P, Jiang W, Weghorst CM, et al. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996;56:36
77. Hollstein M, Sidransky D, Vogelstein B, et al. p53 Mutations in human cancers. Science 1991;253:49
78. Menke-Pluymers MB, Hop WC, Dees J, et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus: the Rotterdam Esophageal Tumor Study Group. Cancer 1993;72:1155